Exascale Labs Holdings Inc. XLAB
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.92% | 8.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.92% | 8.68% | |||
| Cost of Revenue | 4.74% | 11.56% | |||
| Gross Profit | 12.76% | -5.54% | |||
| SG&A Expenses | 54.64% | 25.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.79% | 17.11% | |||
| Operating Income | -23.68% | -62.31% | |||
| Income Before Tax | 30.09% | -147.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.09% | -147.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.09% | -147.90% | |||
| EBIT | -23.68% | -62.31% | |||
| EBITDA | -23.72% | -62.61% | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||